Press Releases
July 26, 2011
Gilead Sciences Announces Second Quarter 2011 Financial Results
- Total Revenues Achieve New Record of $2.14 Billion -
- Second Quarter Non-GAAP EPS of $1.00 -
FOSTER CITY, Calif., Jul 26, 2011 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended June 30, 2011. Total revenues for the second quarter of 2011 were $2.14 billion, up 11 percent compared to total revenues of $1.93 billion for the second quarter of 2010. Net income for the second quarter of 2011 was $746.2 million, or $0.93 per diluted share, compared to net income for the second quarter of 2010 of $712.1 million, or $0.79 per diluted share. Non-GAAP net income for the second quarter of 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $797.7 million, or $1.00 per diluted share, compared to non-GAAP net income for the second quarter of 2010 of $760.7 million, or $0.85 per diluted share.
Product Sales
Product sales increased 13 percent to $2.04 billion for the second quarter of 2011, compared to $1.81 billion in the second quarter of 2010. This increase in sales was driven primarily by Gilead's antiviral franchise, due to strong growth in sales of Atripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and Truvada(R) (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).
Antiviral Franchise
Antiviral product sales increased 11 percent to $1.76 billion in the second quarter of 2011, up from $1.59 billion for the same quarter of 2010.
- Atripla
Sales of Atripla for the treatment of HIV infection increased 15 percent to $822.0 million for the second quarter of 2011, up from $715.8 million in the second quarter of 2010, driven primarily by sales volume growth in the United States and Europe.
- Truvada
Sales of Truvada for the treatment of HIV infection increased 11 percent to $711.3 million for the second quarter of 2011, up from $641.7 million in the second quarter of 2010, driven primarily by sales volume growth in Europe and the United States.
- Viread
Sales of Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B increased 5 percent to $185.7 million for the second quarter of 2011, up from $176.2 million in the second quarter of 2010, due primarily to sales volume growth in Europe and the United States partially offset by lower sales in Latin America.
Letairis
Sales of Letairis(R) (ambrisentan) for the treatment of pulmonary arterial hypertension increased 22 percent to $73.6 million for the second quarter of 2011, up from $60.3 million for the second quarter of 2010, driven primarily by sales volume growth.
Ranexa
Sales of Ranexa(R) (ranolazine) for the treatment of chronic angina increased 42 percent to $86.1 million for the second quarter of 2011, up from $60.5 million for the second quarter of 2010, driven primarily by sales volume growth.
Other Products
Sales of other products were $160.9 million for the second quarter of 2011 compared to $151.6 million for the second quarter of 2010 and included AmBisome(R) (amphotericin B) liposome for injection for the treatment of severe fungal infections, Hepsera(R) (adefovir dipivoxil) for the treatment of chronic hepatitis B, Emtriva(R) (emtricitabine) for the treatment of HIV infection and Cayston(R) (aztreonam for inhalation solution) for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa (P. aeruginosa). The increase in sales of other products was due primarily to sales volume growth of AmBisome in Europe and Latin America and Cayston in the United States. Sales of Cayston were $21.5 million for the second quarter of 2011, up from $10.5 million in the same quarter of 2010.
Royalty, Contract and Other Revenues
Royalty, contract and other revenues from collaborations were $97.7 million in the second quarter of 2011, down 19 percent from $121.2 million in the second quarter of 2010. This decrease was due to lower Tamiflu royalties from F. Hoffmann-La Roche Ltd of $50.6 million in the second quarter of 2011, compared to Tamiflu royalties of $83.8 million in the second quarter of 2010 as pandemic planning initiatives worldwide have declined.
Research and Development
Research and development (R&D) expenses in the second quarter of 2011 were $282.4 million, compared to $231.1 million for the second quarter of 2010. Non-GAAP R&D expenses for the second quarter of 2011, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $262.6 million, compared to $207.4 million for the second quarter of 2010. The increase in non-GAAP R&D expenses was due primarily to increased clinical activities and expenses associated with acquisitions, collaborations and the ongoing growth of Gilead's business.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses in the second quarter of 2011 were $304.3 million, compared to $248.0 million for the second quarter of 2010. Non-GAAP SG&A expenses for the second quarter of 2011, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $276.4 million, compared to $223.5 million for the second quarter of 2010. The increase in non-GAAP SG&A expenses was driven primarily by the impact of the pharmaceutical excise tax resulting from U.S. healthcare reform and increased expenses associated with the ongoing growth of Gilead's business.
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on second quarter 2011 revenues and pre-tax earnings, which includes revenues and expenses generated from outside the United States, was a favorable $27.3 million and $9.7 million, respectively, compared to the second quarter of 2010.
Cash, Cash Equivalents and Marketable Securities
As of June 30, 2011, Gilead had cash, cash equivalents and marketable securities of $5.50 billion compared to $5.32 billion as of December 31, 2010. Gilead generated $1.76 billion of operating cash flow for the first six months of 2011 including $943.3 million in the second quarter of 2011.
Corporate Highlights
In April, Gilead announced the appointment of Muzammil M. Mansuri, PhD, to Senior Vice President, Research and Development Strategy and Corporate Development.
In May, Gilead announced that it had extended its funding support for the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry (IOCB) of the Academy of Sciences of the Czech Republic for an additional five years. Gilead will provide a $1.15 million annual donation to IOCB in order to continue to fund the Research Centre's operations and ongoing research efforts. Gilead has the first option to license inventions that result from the Research Centre's scientific programs and drug discovery efforts.
Under the company's $5.00 billion stock repurchase program authorized in May 2010, Gilead has repurchased approximately $4.29 billion in common stock through June 30, 2011. Total purchase activity was $723.9 million in common stock for the second quarter of 2011.
Product and Pipeline Update
Antiviral Franchise
In June, Gilead announced that it had entered into a license agreement with Tibotec Pharmaceuticals (Tibotec) for the development and commercialization of a new fixed-dose antiretroviral combination product containing Gilead's investigational agent cobicistat and Tibotec's protease inhibitor Prezista(R) (darunavir). In addition, the companies are also negotiating terms for the development and commercialization of a future single-tablet regimen (STR) combining Prezista with Emtriva and the investigational agents GS 7340 and cobicistat. The agreement to develop the fixed-dose combination of cobicistat and Prezista is contingent upon the signing of the agreement to develop the Emtriva, GS 7340, cobicistat and Prezista STR.
Respiratory Franchise
In April, Gilead and MicroDose Therapeutx (MicroDose) announced that the companies had entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus.
Conference Call
At 5:00 p.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss results from its second quarter 2011 as well as provide a general business update. To access the webcast live via the internet, please connect to the company's website at http://www.gilead.com 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-800-299-7089 (U.S.) or 1-617-801-9714 (international) and dial the participant passcode 36874698 to access the call.
A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through July 29, 2011. To access the phone replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 45716316.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the three and six months ended June 30, 2011 and 2010. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on page 6.
Forward-looking Statements
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2011 financial results, including the possibility that its full year 2011 guidance may be revised at a later date; Gilead's ability to sustain growth in revenues for its antiviral, cardiovascular and respiratory franchises; unpredictable variability of Tamiflu royalties and the strong relationship between this royalty revenue and global pandemic planning and supply; the availability of funding for state ADAPs and their ability to purchase at levels to support the number of patients that rely on ADAPs; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Gilead's ability to submit NDAs for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including cobicistat and GS 7340; Gilead's ability to successfully commercialize its products; Gilead's ability to successfully develop its respiratory, cardiovascular and oncology franchises; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including the clinical studies evaluating cobicistat and GS 7340; initiating and completing clinical trials may take longer or cost more than expected, including the clinical studies evaluating cobicistat and GS 7340; the potential for additional austerity measures in European countries that may increase the amount of discount required on Gilead's products; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; Gilead's ability to complete the current $5.00 billion share repurchase program and commence purchases under the additional $5.00 billion share repurchase program due to changes in its stock price, corporate or other market conditions; risks that the funding of the Gilead Sciences Research Center at IOCB will not lead to the discovery of any potential product candidates; risks that Gilead will not sign an agreement to develop the Emtriva, GS 7340, cobicistat and Prezista STR and as a result, the parties will not develop the fixed-dose combination of cobicistat and Prezista; risks that the development and commercialization of cobicistat and Prezista will not be successful; risks that the collaboration with MicroDose will not lead to the commercialization of MDT-637; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market-specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its Annual Report on Form 10-K for the year ended December 31, 2010 and other subsequent disclosure documents filed with the Securities and Exchange Commission and press releases. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Truvada, Viread, Hepsera, Emtriva, AmBisome, Letairis, Cayston and Ranexa are registered trademarks of Gilead Sciences, Inc.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Tamiflu is a registered trademark of F. Hoffmann-La Roche Ltd.
Prezista is a registered trademark of Tibotec, Inc.
For more information on Gilead Sciences, Inc.,please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
| GILEAD SCIENCES, INC. | |||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||||||||||||||||
| (unaudited) | |||||||||||||||||||
| (in thousands, except per share amounts) | |||||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||
| 2011 | 2010 | 2011 | 2010 | ||||||||||||||||
| Revenues: | |||||||||||||||||||
| Product sales | $ | 2,039,588 | $ | 1,806,061 | $ | 3,903,166 | $ | 3,594,124 | |||||||||||
| Royalty, contract and other revenues | 97,665 | 121,163 | 160,181 | 418,953 | |||||||||||||||
| Total revenues | 2,137,253 | 1,927,224 | 4,063,347 | 4,013,077 | |||||||||||||||
| Costs and expenses: | |||||||||||||||||||
| Cost of goods sold | 533,863 | 455,525 | 1,007,974 | 895,955 | |||||||||||||||
| Research and development | 282,403 | 231,066 | 536,849 | 449,730 | |||||||||||||||
| Selling, general and administrative | 304,269 | 248,006 | 599,837 | 513,624 | |||||||||||||||
| Total costs and expenses | 1,120,535 | 934,597 | 2,144,660 | 1,859,309 | |||||||||||||||
| Income from operations | 1,016,718 | 992,627 | 1,918,687 | 2,153,768 | |||||||||||||||
| Interest and other income, net | 11,978 | 18,285 | 25,810 | 33,930 | |||||||||||||||
| Interest expense | (46,107 | ) | (17,764 | ) | (87,323 | ) | (34,719 | ) | |||||||||||
| Income before provision for income taxes | 982,589 | 993,148 | 1,857,174 | 2,152,979 | |||||||||||||||
| Provision for income taxes | 240,130 | 284,021 | 467,412 | 591,758 | |||||||||||||||
| Net income | 742,459 | 709,127 | 1,389,762 | 1,561,221 | |||||||||||||||
| Net loss attributable to noncontrolling interest | 3,768 | 2,934 | 7,606 | 5,741 | |||||||||||||||
| Net income attributable to Gilead | $ | 746,227 | $ | 712,061 | $ | 1,397,368 | $ | 1,566,962 | |||||||||||
|
Net income per share attributable to Gilead common stockholders - basic |
$ | 0.95 | $ | 0.81 | $ | 1.77 | $ | 1.76 | |||||||||||
|
Net income per share attributable to Gilead common stockholders - diluted |
$ | 0.93 | $ | 0.79 | $ | 1.73 | $ | 1.71 | |||||||||||
| Shares used in per share calculation - basic | 784,807 | 881,802 | 790,430 | 891,649 | |||||||||||||||
| Shares used in per share calculation - diluted | 800,800 | 898,753 | 806,462 | 913,819 | |||||||||||||||
| GILEAD SCIENCES, INC. | ||||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION | ||||||||||||||||||
| (unaudited) | ||||||||||||||||||
| (in thousands, except percentages and per share amounts) | ||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||
| June 30, | June 30, | |||||||||||||||||
| 2011 | 2010 | 2011 | 2010 | |||||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||||
| GAAP cost of goods sold | $ | 533,863 | $ | 455,525 | $ | 1,007,974 | $ | 895,955 | ||||||||||
| Acquisition-related amortization of inventory mark-up | - | (2,042 | ) | - | (7,020 | ) | ||||||||||||
| Acquisition-related amortization of purchased intangibles | (17,408 | ) | (14,981 | ) | (34,815 | ) | (29,965 | ) | ||||||||||
| Stock-based compensation expenses | (2,887 | ) | (2,967 | ) | (5,531 | ) | (5,820 | ) | ||||||||||
| Non-GAAP cost of goods sold | $ | 513,568 | $ | 435,535 | $ | 967,628 | $ | 853,150 | ||||||||||
| Product gross margin reconciliation: | ||||||||||||||||||
| GAAP product gross margin | 73.9 | % | 74.8 | % | 74.2 | % | 75.1 | % | ||||||||||
| Acquisition-related amortization of inventory mark-up | - | 0.1 | % | - | 0.2 | % | ||||||||||||
| Acquisition-related amortization of purchased intangibles | 0.9 | % | 0.8 | % | 0.9 | % | 0.8 | % | ||||||||||
| Stock-based compensation expenses | 0.1 | % | 0.2 | % | 0.1 | % | 0.2 | % | ||||||||||
| Non-GAAP product gross margin (1) | 74.9 | % | 75.9 | % | 75.3 | % | 76.3 | % | ||||||||||
| Research and development expenses reconciliation: | ||||||||||||||||||
| GAAP research and development expenses | $ | 282,403 | $ | 231,066 | $ | 536,849 | $ | 449,730 | ||||||||||
| Acquisition-related transaction costs | - | - | (446 | ) | - | |||||||||||||
| Acquisition-related remeasurement of contingent consideration | 418 | - | 418 | - | ||||||||||||||
| Restructuring expenses | (767 | ) | (2,130 | ) | (554 | ) | (4,230 | ) | ||||||||||
| Stock-based compensation expenses | (19,420 | ) | (21,521 | ) | (36,140 | ) | (41,590 | ) | ||||||||||
| Non-GAAP research and development expenses | $ | 262,634 | $ | 207,415 | $ | 500,127 | $ | 403,910 | ||||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 304,269 | $ | 248,006 | $ | 599,837 | $ | 513,624 | ||||||||||
| Acquisition-related transaction costs | (365 | ) | - | (743 | ) | - | ||||||||||||
| Restructuring expenses | 353 | (906 | ) | (1,666 | ) | (13,490 | ) | |||||||||||
| Stock-based compensation expenses | (27,818 | ) | (23,559 | ) | (57,924 | ) | (47,478 | ) | ||||||||||
| Non-GAAP selling, general and administrative expenses | $ | 276,439 | $ | 223,541 | $ | 539,504 | $ | 452,656 | ||||||||||
| Operating margin reconciliation: | ||||||||||||||||||
| GAAP operating margin | 47.6 | % | 51.5 | % | 47.2 | % | 53.7 | % | ||||||||||
| Acquisition-related transaction costs | 0.0 | % | - | 0.0 | % | - | ||||||||||||
| Acquisition-related amortization of inventory mark-up | - | 0.1 | % | - | 0.2 | % | ||||||||||||
| Acquisition-related amortization of purchased intangibles | 0.8 | % | 0.8 | % | 0.9 | % | 0.7 | % | ||||||||||
| Acquisition-related remeasurement of contingent consideration | 0.0 | % | 0.0 | % | 0.0 | % | - | |||||||||||
| Restructuring expenses | 0.0 | % | 0.2 | % | 0.1 | % | 0.4 | % | ||||||||||
| Stock-based compensation expenses | 2.3 | % | 2.5 | % | 2.5 | % | 2.4 | % | ||||||||||
| Non-GAAP operating margin (1) | 50.7 | % | 55.0 | % | 50.6 | % | 57.4 | % | ||||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||||
| GAAP net income attributable to Gilead | $ | 746,227 | $ | 712,061 | $ | 1,397,368 | $ | 1,566,962 | ||||||||||
| Acquisition-related transaction costs | 365 | - | 1,189 | - | ||||||||||||||
| Acquisition-related amortization of inventory mark-up | - | 1,433 | - | 5,090 | ||||||||||||||
| Acquisition-related amortization of purchased intangibles | 13,170 | 10,721 | 26,053 | 21,729 | ||||||||||||||
| Acquisition-related remeasurement of contingent consideration | (313 | ) | - | (313 | ) | - | ||||||||||||
| Restructuring expenses | 324 | 2,061 | 1,661 | 12,849 | ||||||||||||||
| Stock-based compensation expenses | 37,915 | 34,395 | 74,529 | 68,808 | ||||||||||||||
| Non-GAAP net income attributable to Gilead | $ | 797,688 | $ | 760,671 | $ | 1,500,487 | $ | 1,675,438 | ||||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||||
| GAAP diluted earnings per share | $ | 0.93 | $ | 0.79 | $ | 1.73 | $ | 1.71 | ||||||||||
| Acquisition-related transaction costs | 0.00 | - | 0.00 | - | ||||||||||||||
| Acquisition-related amortization of inventory mark-up | - | 0.00 | - | 0.01 | ||||||||||||||
| Acquisition-related amortization of purchased intangibles | 0.02 | 0.01 | 0.03 | 0.02 | ||||||||||||||
| Acquisition-related remeasurement of contingent consideration | (0.00 | ) | - | (0.00 | ) | - | ||||||||||||
| Restructuring expenses | 0.00 | 0.00 | 0.00 | 0.01 | ||||||||||||||
| Stock-based compensation expenses | 0.05 | 0.04 | 0.09 | 0.08 | ||||||||||||||
| Non-GAAP diluted earnings per share (1) | $ | 1.00 | $ | 0.85 | $ | 1.87 | $ | 1.84 | ||||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 800,800 | 898,753 | 806,462 | 913,819 | ||||||||||||||
| Share impact of current stock-based compensation guidance | (2,010 | ) | (1,555 | ) | (1,993 | ) | (1,262 | ) | ||||||||||
| Non-GAAP shares used in per share calculation (diluted) | 798,790 | 897,198 | 804,469 | 912,557 | ||||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||||
| Cost of goods sold adjustments | $ | 20,295 | $ | 19,990 | $ | 40,346 | $ | 42,805 | ||||||||||
| Research and development expenses adjustments | 19,769 | 23,651 | 36,722 | 45,820 | ||||||||||||||
| Selling, general and administrative expenses adjustments | 27,830 | 24,465 | 60,333 | 60,968 | ||||||||||||||
| Total non-GAAP adjustments before tax | 67,894 | 68,106 | 137,401 | 149,593 | ||||||||||||||
| Income tax effect | (16,433 | ) | (19,496 | ) | (34,282 | ) | (41,117 | ) | ||||||||||
| Total non-GAAP adjustments after tax | $ | 51,461 | $ | 48,610 | $ | 103,119 | $ | 108,476 | ||||||||||
| Note: | ||||||||||||||||||
| (1) Amounts may not sum due to rounding | ||||||||||||||||||
| GILEAD SCIENCES, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands) | ||||||||
| June 30, | December 31, | |||||||
| 2011 | 2010 | |||||||
| (unaudited) | (Note 1) | |||||||
| Cash, cash equivalents and marketable securities | $ | 5,499,312 | $ | 5,318,071 | ||||
| Accounts receivable, net | 1,938,645 | 1,621,966 | ||||||
| Inventories | 1,321,615 | 1,203,809 | ||||||
| Property, plant and equipment, net | 721,884 | 701,235 | ||||||
| Intangible assets | 2,128,410 | 1,425,592 | ||||||
| Other assets | 1,084,274 | 1,321,957 | ||||||
| Total assets | $ | 12,694,140 | $ | 11,592,630 | ||||
| Current liabilities | $ | 2,310,841 | $ | 2,464,950 | ||||
| Long-term liabilities | 4,171,968 | 3,005,843 | ||||||
| Stockholders' equity (Note 2) | 6,211,331 | 6,121,837 | ||||||
| Total liabilities and stockholders' equity | $ | 12,694,140 | $ | 11,592,630 | ||||
| Notes: | ||||||||
| (1) | Derived from audited consolidated financial statements at that date. | |||||||
| (2) | As of June 30, 2011, there were 776,405 shares of common stock issued and outstanding. | |||||||
| GILEAD SCIENCES, INC. | ||||||||||||||
| PRODUCT SALES SUMMARY | ||||||||||||||
| (unaudited) | ||||||||||||||
| (in thousands) | ||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||
| June 30, | June 30, | |||||||||||||
| 2011 | 2010 | 2011 | 2010 | |||||||||||
| Antiviral products: | ||||||||||||||
| Atripla - U.S. | $ | 510,237 | $ | 466,819 | $ | 973,004 | $ | 922,720 | ||||||
| Atripla - Europe | 267,153 | 221,149 | 520,210 | 438,697 | ||||||||||
| Atripla - Other International | 44,602 | 27,836 | 73,290 | 47,259 | ||||||||||
| 821,992 | 715,804 | 1,566,504 | 1,408,676 | |||||||||||
| Truvada - U.S. | 334,064 | 317,522 | 654,177 | 644,339 | ||||||||||
| Truvada - Europe | 322,007 | 278,373 | 621,163 | 575,901 | ||||||||||
| Truvada - Other International | 55,230 | 45,787 | 109,072 | 79,241 | ||||||||||
| 711,301 | 641,682 | 1,384,412 | 1,299,481 | |||||||||||
| Viread - U.S. | 80,228 | 78,787 | 152,708 | 156,794 | ||||||||||
| Viread - Europe | 86,123 | 71,004 | 162,135 | 144,147 | ||||||||||
| Viread - Other International | 19,366 | 26,381 | 39,269 | 55,917 | ||||||||||
| 185,717 | 176,172 | 354,112 | 356,858 | |||||||||||
| Hepsera - U.S. | 14,765 | 19,470 | 28,639 | 41,035 | ||||||||||
| Hepsera - Europe | 20,582 | 28,551 | 42,070 | 61,926 | ||||||||||
| Hepsera - Other International | 3,309 | 3,313 | 6,043 | 6,497 | ||||||||||
| 38,656 | 51,334 | 76,752 | 109,458 | |||||||||||
| Emtriva - U.S. | 3,914 | 4,135 | 7,816 | 8,379 | ||||||||||
| Emtriva - Europe | 1,705 | 1,684 | 3,390 | 3,559 | ||||||||||
| Emtriva - Other International | 1,113 | 926 | 2,102 | 1,963 | ||||||||||
| 6,732 | 6,745 | 13,308 | 13,901 | |||||||||||
| Total Antiviral products - U.S. | 943,208 | 886,733 | 1,816,344 | 1,773,267 | ||||||||||
| Total Antiviral products - Europe | 697,570 | 600,761 | 1,348,968 | 1,224,230 | ||||||||||
| Total Antiviral products - Other International | 123,620 | 104,243 | 229,776 | 190,877 | ||||||||||
| 1,764,398 | 1,591,737 | 3,395,088 | 3,188,374 | |||||||||||
| AmBisome | 88,625 | 78,174 | 167,131 | 155,223 | ||||||||||
| Letairis | 73,637 | 60,348 | 135,811 | 115,847 | ||||||||||
| Ranexa | 86,077 | 60,460 | 154,370 | 111,703 | ||||||||||
| Other products | 26,851 | 15,342 | 50,766 | 22,977 | ||||||||||
| 275,190 | 214,324 | 508,078 | 405,750 | |||||||||||
| Total product sales | $ | 2,039,588 | $ | 1,806,061 | $ | 3,903,166 | $ | 3,594,124 | ||||||
SOURCE: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Susan Hubbard, 650-522-5715
Media
Amy Flood, 650-522-5643